Advertisement

Cardiovascular Risk, Glucose and Targets for Management of Diabetes in Older People

  • Gillian Hawthorne
  • Alison J. Yarnall
Chapter

Abstract

Older people make up a large proportion of people with diabetes, and although there is much guidance for the treatment of people with type 2 diabetes, these do not take into account the real situation in the elderly such as co-morbidities and frailty. Indeed, frail elderly are routinely excluded from large clinical trials, where cardiovascular risk, hypertension and risk of death are so much higher. This chapter discusses current trial evidence for cardiovascular risk, glucose and targets for management of diabetes in older people, allowing for the heterogeneous nature of this group and offering some practical guidance for practising clinicians in this difficult area.

Keywords

Glycaemic Control Severe Hypoglycaemia Major Cardiovascular Event Target Blood Pressure Tight Glucose Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Boult C, Dowd B, McCaffrey D, Boult L, Hernandez R, Krulewitch H. Screening elder at for risk of hospital admission. J Am Geriatr Soc 1993: 41:811–817PubMedGoogle Scholar
  2. 2.
    Hornick T, Aron DC. Managing diabetes in the elderly: Go easy, individualise. Cleveland Clinic J Med 2008: 75:70–78CrossRefGoogle Scholar
  3. 3.
    Rodriguez A, Muller DC, Engelhardt M, Andres R. Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging. Metabolism Clin Exper 2005: 54:542–547Google Scholar
  4. 4.
    Crandall J, Barzilai N. Treatment of diabetes mellitus in older people: oral therapy options. J Am Geriatr Soc 2003: 51:272–274PubMedCrossRefGoogle Scholar
  5. 5.
    Szoke E, Shrayeff MZ, Messing S et al. Effect of aging on glucose homeostasis. Accelerated deterioration of beta cell function in individuals with impaired glucose tolerance. Diabetes Care 2008: 31: 539–543PubMedCrossRefGoogle Scholar
  6. 6.
    Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003: 284: E7-12PubMedGoogle Scholar
  7. 7.
    Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 2008: 337: a236PubMedCrossRefGoogle Scholar
  8. 8.
    Bethel MA, Sloan FA, BelskyD, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med 2007: 167:921–927PubMedCrossRefGoogle Scholar
  9. 9.
    Gerstein HC, Mann JF, Yi Q, Zinman B, Dineen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and non diabetic individuals. JAMA 2001: 286: 421–426PubMedCrossRefGoogle Scholar
  10. 10.
    Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care 2004: 27:699–703PubMedCrossRefGoogle Scholar
  11. 11.
    Kronmal RA, Barzilay JI, Smith NL et al. Mortality in pharmacologically treated older adults with diabetes: The Cardiovascular Health Study 1989–2001. PloS Med 2006: 3:e400 DOI 10 1371PubMedCrossRefGoogle Scholar
  12. 12.
    California Healthcare Foundation/American Geriatrics Society panel on improving care for elders with diabetes. Guidelines for improving the care of older people with diabetes mellitus. JAGS 2003: 51:S265-S280CrossRefGoogle Scholar
  13. 13.
    Stratton IM, Adler AI, Neil HAWet al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes [UKPDS 35]: a prospective observational study. BMJ 2000: 321:405–412PubMedCrossRefGoogle Scholar
  14. 14.
    Shorr RI, Franse LV, Resnick HE et al Glycemic control of older adults with type 2 diabetes: Findings from the third National Health and Nutrition Examination Survey, 1988—94. J Am Geriatr Soc 2000: 48:264–267PubMedGoogle Scholar
  15. 15.
    United Kingdom Prospective Diabetes Study [UKPDS] group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998: 317:707–713Google Scholar
  16. 16.
    Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998: 339:229–234PubMedCrossRefGoogle Scholar
  17. 17.
    Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic –based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996: 276:1886–1892PubMedCrossRefGoogle Scholar
  18. 18.
    Katakura M, Naka M, Kondo T et al. Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects: Nagano study. Diabetes Care 2003: 26:638–644PubMedCrossRefGoogle Scholar
  19. 19.
    Hubbard RE, Andrew MK, Fallah N, Rockwood K. Comparison of the prognostic importance of diagnosed diabetes, co-morbidity and frailty in older people. Diabetic Med 2010: 27:603–608PubMedCrossRefGoogle Scholar
  20. 20.
    Rodriguez J, Weiss C, Boyd C, Leff B, Wolff J. A systematic literature review of the trial evidence base for treating diabetes and other chronic conditions in older adults. AGS 2010 S111Google Scholar
  21. 21.
    United Kingdom Prospective Diabetes Study [UKPDS] group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33]. Lancet 1998: 352:837–853CrossRefGoogle Scholar
  22. 22.
    Holman RR, Paul SJ, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008: 358:580–591CrossRefGoogle Scholar
  23. 23.
    The ADVANCE Collaboration Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008: 358: 2560–72CrossRefGoogle Scholar
  24. 24.
    The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008: 358: 2545–59CrossRefGoogle Scholar
  25. 25.
    Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009: 360: 129–139PubMedCrossRefGoogle Scholar
  26. 26.
    Kagansky N, Levy S, Rimon E et al. Hypoglycaemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003: 163: 1681–1686CrossRefGoogle Scholar
  27. 27.
    Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycaemic episodes and risk of dementia in older patients with type 2 diabetes. JAMA 2009: 301:1565–1572PubMedCrossRefGoogle Scholar
  28. 28.
    Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Poole CD. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010: 375:481–489PubMedCrossRefGoogle Scholar
  29. 29.
    Tilling LM, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications 2006: 20:158–162PubMedCrossRefGoogle Scholar
  30. 30.
    Rakel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008: 34: 193–205PubMedCrossRefGoogle Scholar
  31. 31.
    Schwartz A, Vittinghoff E, Sellmeyer DE et al. Diabetes –related complications, glycemic control, and falls in older adults. Diabetes Care 2008: 31:391–396PubMedCrossRefGoogle Scholar
  32. 32.
    Greenfield S, Billimek J, Pellegrini F, De Berardis G, Nicolucci A, Kaplan S. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. Ann Intern Med 2009: 151:854–860PubMedGoogle Scholar
  33. 33.
    Huang ES, Zhang Q, Gandra N, Marshall H, Chin MD, Meltzer DO. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008: 149:11–19PubMedGoogle Scholar
  34. 34.
    National Institute for Health and Clinical Excellence. Type 2 diabetes. The management of type 2 diabetes. NICE clinical guideline 87 May 2009Google Scholar
  35. 35.
    European Diabetes Working Party for Older People. Clinical Guidelines for Type 2 Diabetes Mellitus 2004. Available on: www.instituteofdiabetes.org
  36. 36.
    Papa G, Fedele V, Rezze MR et al. Safety of type 2 diabetes treatment with repaglinide compared with Glibenclamide in elderly people: A randomised, open-label, two-period cross-over trial. Diabetes Care 2006: 29: 1918–1920PubMedCrossRefGoogle Scholar
  37. 37.
    Nissen SE, Wolsky K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007: 356: 2457–2471PubMedCrossRefGoogle Scholar
  38. 38.
    Yoke YK, Singh S, Furberg CD. Long-term use of Thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009: 180: 32–39CrossRefGoogle Scholar
  39. 39.
    National Institute for Health and Clinical Excellence. Type 2 Diabetes- Newer Agents (Partial Update of CG66). London: Royal College of Physicians 2009Google Scholar
  40. 40.
  41. 41.
    NICE and Diabetes: A Summary of Relevant Guidelines. November 2009. NHS DiabetesGoogle Scholar
  42. 42.
    Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes in the elderly: role of incretin therapies. Drugs and Aging 2008: 25:913–25PubMedCrossRefGoogle Scholar
  43. 43.
    Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009: 11:804–812PubMedCrossRefGoogle Scholar
  44. 44.
    Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment and control in older US adults: data from the National Health and Nutrition Survey 1988 to 2004. JAGS 2007: 55:1056–1065CrossRefGoogle Scholar
  45. 45.
    Blood pressure lowering treatment trialists’ collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005: 165: 1410–1419CrossRefGoogle Scholar
  46. 46.
    Beckett NS, Peters R, Fletcher AEet al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008: 358:1887–1898PubMedCrossRefGoogle Scholar
  47. 47.
    Ninomiya T, Zoungas S, Neal B, Woodward M, Patel A eta al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertension 2010: 28:1141–1149Google Scholar
  48. 48.
    ACCORD Study Group. Effects of intensive blood pressure control in Type 2 diabetes mellitus. N Engl J Med 2010: 362:1575–1585CrossRefGoogle Scholar
  49. 49.
    Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009; CD004349Google Scholar
  50. 50.
    Aronow WS. Treatment of hypertension in the elderly. Geriatrics 2008: 63:21–25PubMedGoogle Scholar
  51. 51.
    Van Hateren KJJ, Landman GWD, Kleefstra N et al. Lower blood pressure associated with higher mortality in elderly diabetic patients (ZODIAC-12). Age Ageing 2010: 39:603–609PubMedCrossRefGoogle Scholar
  52. 52.
    Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC VII report. JAMA 2003: 289:2560–2572PubMedCrossRefGoogle Scholar
  53. 53.
    Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C et al. Metabolic and clinical outcomes in non diabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension. Diabetes Care 2008: 31:353–360PubMedCrossRefGoogle Scholar
  54. 54.
    Baignent C, Keech A, Kearney PM, Blackwell L et al. Efficacy and safety of cholesterol-lowering treatment: a prospective meta-­analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005: 366:1267–1279CrossRefGoogle Scholar
  55. 55.
    Bandolier. Statins in older people.http://www.medicine.ox.ac.uk/bandolier/bandb117/bii7-4.html accessed August 2010
  56. 56.
    Vergouwen MD, de Haan RJ, Vermeulen M et al. Statin treatment and the occurrence of haemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008: 39:497–502PubMedCrossRefGoogle Scholar
  57. 57.
    Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease [PROSPER]: a randomised controlled trial. Lancet 2002: 360:1623–1630PubMedCrossRefGoogle Scholar
  58. 58.
    Brekke M, Hunskaar S, Straand J. Antihypertensive and lipid lowering treatment in 70–74 year old individuals –predictors for treatment and blood –pressure control: a population based survey. The Hordal and Health Study [HUSK]. BMC Geriatrics 2006:6:16PubMedCrossRefGoogle Scholar
  59. 59.
    Safford M, Eaton L, Hawley G et al. Disparities in use of lipid-­lowering medications among people with type 2 diabetes mellitus. Arch Intern Med 2003: 163:922–929CrossRefGoogle Scholar
  60. 60.
    Chin-Dusting JPF, Dart AM. Age and the treatment gap in the use of statins. Lancet 2003: 361:1925Google Scholar
  61. 61.
    Mungall MM, Gaw A, Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 2003: 20:263–75PubMedCrossRefGoogle Scholar
  62. 62.
    Clarke R, Emberson J, Parish S et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med 2007: 167:1373–1378PubMedCrossRefGoogle Scholar
  63. 63.
    Krumholz H, Hayward R. Shifting views on lipid lowering therapy. BMJ 2010: 341:332–333CrossRefGoogle Scholar
  64. 64.
    De Berardis G, Sacco M, Strippoli GFM, Pewllegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009: 339:b4531PubMedCrossRefGoogle Scholar
  65. 65.
    Sinclair A, Conroy SP, Bayer AJ. Impact of diabetes on physical function. Diabetes Care 2008: 31:233–235PubMedCrossRefGoogle Scholar
  66. 66.
    Finucane FM, Sharp SJ, Purslow LR et al. The effects of aerobic exercise on metabolic risk, insulin sensitivity and intrahepatic lipid in healthy older people from the Hertfordshire Cohort Study: a randomized controlled trial. Diabetologia 2010: 53:624–631PubMedCrossRefGoogle Scholar
  67. 67.
    Martins RA, Verissimo MT, Coelho e Silva MJ, Cummings SP, Teixeira AM. Effects of aerobic and a strength –based training on metabolic health indicators in older adults. Lipids in Health and Disease 2010: 9:76–82PubMedCrossRefGoogle Scholar
  68. 68.
    Castaneda C, Layne JE, Munoz-Orians L et al. A randomized ­controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002: 25:2335–2341PubMedCrossRefGoogle Scholar
  69. 69.
    Manin D, Sweeney K, Heath I. Preventive health care in elderly people needs rethinking. BMJ 2007: 335:285–287CrossRefGoogle Scholar
  70. 70.
    Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001: 285:2750–2756PubMedCrossRefGoogle Scholar
  71. 71.
    Fraenkel L, Fried T. Individualised medical decision making. Arch Intern Med 2010: 170:566–569PubMedCrossRefGoogle Scholar
  72. 72.
    Huang ES, Gorawara –Bhat R, Chin MH. Self reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 2005: 53:306–311PubMedCrossRefGoogle Scholar
  73. 73.
    Belcher VN, Fried TR, Agostini JV, Tinetti ME. Views of older adults on patient participation in medication related decision making. J Gen Intern Med 2006: 21:298–303PubMedCrossRefGoogle Scholar
  74. 74.
    Trief PM, Teresi JA, Eimicke JP, Shea S, Weinstock RS. Improvement in diabetes self-efficacy and glycaemic control using telemedicine in a sample of older, ethnically diverse individuals who have diabetes: the IDEATel project. Age and Ageing 2009: 38:219–225PubMedCrossRefGoogle Scholar
  75. 75.
    Bandura A. Social cognitive theory: an agentic approach. Annu Rev Psychol 2001: 52: 1–26PubMedCrossRefGoogle Scholar
  76. 76.
    Heisler M, Cole I, Weir D, Kerr EA, Hayward RA. Does physician communication influence older patients diabetes self –management and glycemic control? Results from the Health and Retirement Study[HRS]. J Gerontology 2007: 62:1435–1442Google Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Gillian Hawthorne
    • 1
  • Alison J. Yarnall
    • 2
  1. 1.Newcastle Diabetes Centre The Newcastle upon Tyne HospitalsNHS Foundation TrustNewcastle upon TyneUK
  2. 2.Clinical Ageing Research UnitUniversity of Newcastle upon TyneNewcastle upon TyneUK

Personalised recommendations